You are here

Intranasal Glutathione in Parkinson's Disease

Active
Neurology
Laurie Mischley, ND
January 2010 – December 2014

Parkinson's disease (PD) is considered a progressive and irreversible neurodegenerative disease. Current therapies improve disease symptoms, however none alter the underlying degenerative course. Research suggests the loss of brain glutathione, a powerful antioxidant, is one of the earliest changes to occur in the brain of PD patients and the magnitude of glutathione depletion parallels the severity of PD. This study will look at the use of intranasal glutathione in PD patients to determine safety, tolerability, and the impact on PD symptoms.